SOLICITATION NOTICE
65 -- Reagents and consumables for the AB SOLiD sequencing system.
- Notice Date
- 11/19/2009
- Notice Type
- Presolicitation
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100020-NG
- Archive Date
- 12/22/2009
- Point of Contact
- Malinda L Holdcraft, Phone: (301) 402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
holdcram@exchange.nih.gov, cr214i@nih.gov
(holdcram@exchange.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR), plans to procure on a sole source basis; Library construction kits (Fragment, Mate Paired, and Long Mate Paired); Templated beads preparation (ePCR) kits; SOLiD™ sequencing kits - kits include SOLiD™ Mate-Paired Library Sequencing Kit – Master Mix 35, SOLiD™ Mate-Paired Library Sequencing Kit – Master Mix 50, and SOLiD™ Fragment Library Sequencing Kit – Master Mix 50; and Software and hardware upgrades for the government owned Applied Biosystems SOLiD™ 3 System from Applied Biosystems, part of Life Technology Corporation; 850 Lincoln Centre Drive; Foster City, California 94404. The supplies and services herein are commercial as defined in FAR Part 12, and this acquisition is being made in accordance with the test program for using simplified procedures for certain commercial items as authorized in FAR Part 13.5. The North American Industry Classification System code is 325413 and the business size standard is 500 employees. The purpose of this acquisition is to pursue the comprehensive whole genome sequencing of cancer specimens, including those from rhabdomyosarcoma (RMS) patients with paired germ line DNA. In addition, the products will also be used to perform next generation sequencing of the RMS and other cancer transcriptomes. The reagents and consumables associated with this acquisition are not generic, and as such, Applied Biosystems, part of Life Technology Corporation, is the only known manufacturer for the essential reagents and consumables for sequencing on the AB SOLiD™ instrument. Only these reagents and consumables operate in the SOLiD instrument as Applied Biosystems holds patent rights and exclusive licenses specific to each product category. The NCI also requires the uniqueness of the SOLiD Whole Transcritpome Kit for strand specific determinations. High throughput sequencing has revealed that transcripts are also synthesized from the anti-sense strand of DNA. Furthermore, other types of non-coding RNA (e.g., miRNA) have been shown to represent a significant fraction of the genome and to be transcribed from both strands of DNA. For this reason, it is important to know to which strand of the DNA each RNA transcript maps. Because the kit is not limited to poly (A+) RNA, a more thorough investigation of the complexity of the transcriptome can be performed. The kit uses Applied Biosystems’ proprietary Ligase Enhanced Genome Detection (LEGenD™) technology to convert RNA into a library of double-stranded DNA molecules. Because the adapters are added simultaneously and in a directional manner, genomic DNA strand specificity is maintained. Applied Biosystems is the only source known to NCI that can provide the aforementioned proprietary reagents and supplies needed to continue the mission of the NCI CCR. In addition, this is the only known patented technology available to run on the AB SOLiD™ system, coupled with the highest tag count available. Period of Performance shall be from award through 12 months, with one, 12 month option period. In addition, this is a firm fixed price, indefinite delivery/indefinite quantity (IDIQ) type contract. Only one (1) award will be made as a result of this notice. This is not a request for competitive quotations. However, if any interested party believes it can provide the above supplies, it may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow NCI to determine if it can meet the above specifications described herein. Capability statements must be received in the NCI Office of Acquisition by 11:00 AM ET on December 07, 2009. No electronic capability statements will be received via electronic mail or fax. If you have questions, please contact Malinda Holdcraft, Contract Specialist via electronic mail at holdcram@exchange.nih.gov or fax - 301 402-4513. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must have current registration and certification in the Central Contractor Registration (CCR), www.ccr.gov and the Online Representations and Certifications Application (ORCA) http://orca.bpn.gov. Please reference NCI-100020-NG on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100020-NG/listing.html)
- Place of Performance
- Address: USA, United States
- Record
- SN02007685-W 20091121/091120000053-b309cdb46142e63559b245be30ffc5eb (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |